<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of mucous membrane pemphigoid</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of mucous membrane pemphigoid</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of mucous membrane pemphigoid</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kim B Yancey, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John J Zone, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 16, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H10872275"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mucous membrane pemphigoid (MMP) is a rare, chronic, autoimmune, subepithelial blistering and erosive disease that affects the mucosal surfaces of the mouth (gingiva, movable mucosa, tongue, and palate), eyes, nose, nasopharynx, hypopharynx, larynx, esophagus, genitals, and/or anus  (<a class="graphic graphic_picture graphicRef52208 graphicRef63997 graphicRef73874" href="/d/graphic/52208.html" rel="external">picture 1A-C</a>) [<a href="#rid1">1,2</a>]. Limited cutaneous involvement (typically localized to the head, neck, or upper trunk) also may be present. (See  <a class="medical medical_review" href="/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Clinical features of mucous membrane pemphigoid'</a>.)</p><p>MMP may cause significant morbidity due to the tissue destruction and functional limitations that result from chronic mucosal inflammation, pain, and scarring. As examples, gingival inflammation and scarring may lead to gingival recession and loss of teeth, conjunctival scarring may contribute to blindness, and laryngeal scarring may result in airway loss.</p><p>The treatment of MMP, particularly MMP involving the oral cavity, will be reviewed here. The management of ocular MMP (ocular cicatricial pemphigoid) and the clinical manifestations and diagnosis of MMP are discussed separately. (See  <a class="medical medical_review" href="/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid"</a> and  <a class="medical medical_review" href="/d/html/16864.html" rel="external">"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid"</a> and  <a class="medical medical_review" href="/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a> and  <a class="medical medical_review" href="/d/html/15297.html" rel="external">"Management and prognosis of bullous pemphigoid"</a>.)</p><p class="headingAnchor" id="H10872348"><span class="h1">APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>The primary goals of the treatment of mucous membrane pemphigoid (MMP) are to halt the progression of the disease, improve symptoms, and prevent adverse sequelae of chronic tissue inflammation and scarring [<a href="#rid3">3,4</a>]. Few high-quality trials have evaluated interventions for MMP [<a href="#rid5">5</a>]. Thus, treatment is largely guided by clinical experience and small uncontrolled studies. Consistent use of the recommended measures for disease activity and treatment outcomes published in 2014 may aid in the systematic interpretation of data from future studies [<a href="#rid6">6</a>].</p><p>The approach to therapy is influenced by the following clinical factors [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Site(s) of involvement</p><p class="bulletIndent1"><span class="glyph">●</span>Severity of disease</p><p class="bulletIndent1"><span class="glyph">●</span>Rate of disease progression</p><p></p><p>While patients with limited disease of the oral mucosa may be successfully managed with local therapies, patients with even mild involvement of sites associated with a higher risk of serious morbidity (ocular, genital, nasopharyngeal, laryngeal, or esophageal MMP) require systemic agents as initial therapy. Patients with severe or rapidly progressive disease also benefit from early treatment with systemic agents. (See <a class="local">'Extraoral disease'</a> below and  <a class="medical medical_review" href="/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid"</a>.)</p><p>After clinical remission is attained, treatment is slowly tapered. The pace of tapering should be slow (eg, over several months) to minimize the risk for disease flares. If discontinuation of all therapy is not possible due to relapses, patients are maintained on the lowest effective topical or systemic maintenance regimen.</p><p>In addition to pharmacologic interventions, proper management of MMP includes consideration of the need for multidisciplinary care. Based upon the sites of known or suspected involvement, comanagement between dermatologists, dentists, ophthalmologists, otolaryngologists, urologists, internists, gastroenterologists, or colorectal surgeons is often needed. Whenever feasible, patients should be managed by clinicians experienced in the treatment of MMP. (See <a class="local">'Extraoral disease'</a> below.)</p><p class="headingAnchor" id="H86588195"><span class="h1">ORAL DISEASE</span><span class="headingEndMark"> — </span>The oral cavity is the most common site of mucous membrane pemphigoid (MMP)  (<a class="graphic graphic_picture graphicRef52208 graphicRef63997 graphicRef73874" href="/d/graphic/52208.html" rel="external">picture 1A-C</a>) [<a href="#rid7">7</a>]. Our approach to the treatment of oral MMP varies based upon the severity of disease. (See  <a class="medical medical_review" href="/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Clinical features of mucous membrane pemphigoid'</a>.)</p><p class="headingAnchor" id="H10872355"><span class="h2">Mild disease</span><span class="headingEndMark"> — </span>Patchy, localized involvement of the oral mucosa and skin can often be treated effectively with local therapy. Topical corticosteroids are the first-line local treatment due to extensive clinical experience with the use of these agents for MMP. Topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and intralesional corticosteroid injections are additional therapeutic options.</p><p class="headingAnchor" id="H15289514"><span class="h3">Topical corticosteroids</span><span class="headingEndMark"> — </span>Topical corticosteroids, which may be used as monotherapy for patients with mild oral disease or as an adjunct to systemic treatment in patients with more extensive disease, are important components of the therapeutic arsenal. Randomized trials to evaluate the efficacy of topical corticosteroids have not been performed. As noted above, clinical experience supports the use of these agents [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H174265188"><span class="h4">Administration</span><span class="headingEndMark"> — </span>Class I, super high-potency topical corticosteroids (eg, 0.05% <a class="drug drug_general" data-topicid="9276" href="/d/drug information/9276.html" rel="external">clobetasol</a> propionate) in an ointment or gel base are recommended by most experts for treatment of oral MMP  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 1</a>). Gels and ointments can be easily applied to mucosal surfaces and lack the gritty texture of topical corticosteroids formulated in dental pastes that some patients find unpleasant.</p><p>Treatment is applied two to four times per day immediately after the affected areas are dried with soft disposable tissue paper. Drying the mucosa prior to application may enhance the adherence of the medication to the treatment area. Patients should avoid eating or drinking for at least 30 minutes after application.</p><p>We encourage patients to do one of their daily applications immediately before bed since oral secretions are lessened during sleep. This may allow the medication to stay in place for a longer period.</p><p>An alternative mode of topical corticosteroid administration for patients who find the direct application of topical corticosteroids difficult is the use of 5 mL of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (0.1 mg/mL) as a swish and spit mouth rinse two to three times per day. Patients treated in this manner should be instructed to avoid swallowing the medication.</p><p>Drug delivery via gingival trays is an additional method of drug administration that can be useful for patients with gingival involvement. The trays aid in the application of topical corticosteroids to lesional sites under occlusion [<a href="#rid8">8,9</a>]. The gingival tray should be fashioned in soft vinyl and fitted to cover the patient's gingiva (ie, not the patient's teeth). Trays containing topical corticosteroids are left in place for 10 to 20 minutes per treatment.</p><p>Beneficial effects of topical corticosteroid therapy are usually evident within several weeks. If topical corticosteroid therapy is successful, treatment can be tapered slowly (over several months) by reducing the frequency of application and using lower-potency agents. In our experience, patients who experience disease flares during topical corticosteroid tapering may benefit from a maintenance regimen in which treatment with a topical corticosteroid is alternated with topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> (eg, topical tacrolimus applied Monday to Friday and a topical corticosteroid applied on weekends). Intermittent use of topical corticosteroids may help to reduce the risk for corticosteroid side effects.</p><p class="headingAnchor" id="H1770885"><span class="h4">Side effects</span><span class="headingEndMark"> — </span>Examples of potential adverse effects of topical corticosteroid therapy include mucosal atrophy, oropharyngeal candidiasis, and dyspepsia. Topical or systemic antifungal therapy is effective for secondary candidiasis. (See  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H15289616"><span class="h3">Topical tacrolimus</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, a calcineurin inhibitor, appears to be effective for some patients. Case reports document marked improvement in oral MMP with topical tacrolimus, including some patients who failed to respond well to topical corticosteroids [<a href="#rid10">10-12</a>].</p><p>Topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment initially is applied two to three times per day and is tapered as tolerated. The method of administration mirrors that for topical corticosteroid treatment (see <a class="local">'Administration'</a> above). The higher cost of tacrolimus relative to many topical corticosteroids prohibits use of this therapy for some patients.</p><p>A transient burning sensation may occur following the application of topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>. In addition, concern has been raised regarding a relationship between the use of topical calcineurin inhibitors and cancer, resulting in the issuing of a public health advisory by the US Food and Drug Administration [<a href="#rid13">13</a>]. However, a causative relationship has not been proven. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Topical calcineurin inhibitors'</a>.)</p><p class="headingAnchor" id="H15289522"><span class="h3">Intralesional corticosteroids</span><span class="headingEndMark"> — </span>Intralesional corticosteroid therapy is an option for disease in the anterior aspects of the mouth that does not respond sufficiently to other local measures. Support for the efficacy of this treatment is limited to clinical experience [<a href="#rid14">14</a>].</p><p>Injections should be placed into the superficial submucosa beneath erosions; deeper injections may increase the risk for mucosal atrophy. We inject 0.1 to 0.5 mL of <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide (10 mg/mL) per injection site. We limit the total dose of triamcinolone acetonide administered during a single treatment session to 20 mg. (See  <a class="medical medical_review" href="/d/html/5568.html" rel="external">"Intralesional corticosteroid injection", section on 'Adverse effects and pitfalls'</a>.)</p><p class="headingAnchor" id="H15289668"><span class="h2">Moderate to severe disease</span><span class="headingEndMark"> — </span>Patients with oral MMP that fails to respond adequately to local therapy or who present with widespread oral disease may benefit from systemic agents. Systemic glucocorticoids and <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> are frequently used to manage these patients [<a href="#rid1">1</a>]. The local therapies used for mild oral MMP are often prescribed as adjunctive agents. (See <a class="local">'Mild disease'</a> above.)</p><p class="headingAnchor" id="H6525575"><span class="h3">Systemic glucocorticoids</span><span class="headingEndMark"> — </span>Systemic glucocorticoids are frequently used for oral MMP [<a href="#rid1">1</a>]. However, data to support the efficacy of systemic glucocorticoids are limited. Our treatment regimen for systemic glucocorticoids is based upon clinical experience.</p><p>We typically treat patients with 0.25 to 0.5 mg/kg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> per day given as a single morning dose. Since long-term treatment with systemic glucocorticoids is unfavorable due to drug-related side effects, we taper and discontinue prednisone within six months, if possible. Topical therapy or a systemic drug (eg, <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil) is used as a glucocorticoid-sparing agent to maintain clinical improvement during and after prednisone tapering. Patients who respond insufficiently to 0.25 to 0.5 mg/kg of prednisone may require higher doses of prednisone or alternative therapies. (See <a class="local">'Severe and refractory disease'</a> below.)</p><p>Systemic glucocorticoid therapy may lead to endocrinologic, musculoskeletal, cardiovascular, and other system abnormalities. The adverse effects of systemic glucocorticoids are reviewed separately. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p class="headingAnchor" id="H15289599"><span class="h3">Dapsone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">Dapsone</a> in doses of 50 to 200 mg per day may be used for oral MMP that cannot be adequately managed with local therapy [<a href="#rid15">15</a>]. Data on the efficacy of dapsone for oral manifestations of MMP are limited to a few uncontrolled studies and case series in which some patients improved after the initiation of dapsone therapy [<a href="#rid15">15-21</a>]. As an example, dapsone appeared to be effective in a retrospective study that included 11 patients with MMP localized to the gingiva. Treatment with dapsone (up to 150 mg per day) for at least 12 weeks was associated with major or complete improvement in 10 patients (91 percent) [<a href="#rid20">20</a>]. Additional support for the use of dapsone comes from studies performed in patients with ocular MMP [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid", section on 'Mild to moderate disease'</a>.)</p><p><a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">Dapsone</a> is initiated at a low dose (eg, 25 to 50 mg per day) and is titrated upward as tolerated (eg, 25 to 50 mg per week depending on patient age and tolerance). The slow dose escalation is accompanied by close laboratory monitoring for adverse effects.</p><p>Hemolysis and methemoglobinemia are pharmacologic side effects of <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> that occur in virtually all treated patients. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have an increased risk for adverse consequences due to these pharmacologic effects of dapsone. We assess for G6PD deficiency prior to initiating treatment. Other potentially severe (and usually rare) adverse effects of dapsone include leukopenia, agranulocytosis, aplastic anemia, hypersensitivity reactions, and neuropathy (usually motor, though a sensory component may coexist). More common adverse effects include headache, nausea, weakness, dizziness, and fatigue. (See  <a class="medical medical_review" href="/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>.)</p><p>Due to the potential for serious hematologic side effects, laboratory monitoring is necessary for patients receiving <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> therapy. We typically obtain a complete blood count (CBC) with differential, liver function tests, and renal function tests prior to the start of therapy and repeat the CBC with differential every week during the first month of therapy and twice monthly for the subsequent two months. Thereafter, monitoring of the CBC, liver function tests, and renal function tests can be performed every three to four months [<a href="#rid24">24</a>]. The more frequent monitoring schedule is repeated following dose increases.</p><p class="headingAnchor" id="H10872369"><span class="h2">Severe and refractory disease</span><span class="headingEndMark"> — </span>Aggressive immunosuppressive regimens and biologic therapies may lead to improvement in patients with severe MMP that cannot be managed with the interventions described above. The potential for serious adverse effects and/or high cost of these agents limit their use as first-line therapy.</p><p class="headingAnchor" id="H15289572"><span class="h3">Immunosuppressants</span><span class="headingEndMark"> — </span>Immunosuppressants, such as <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, are typically used in combination with systemic glucocorticoids for patients with severe, refractory oral MMP [<a href="#rid25">25</a>]. Support for the use of these agents primarily stems from uncontrolled studies of patients with ocular involvement and clinical experience with patients with oral disease [<a href="#rid1">1,22,26-32</a>]. (See  <a class="medical medical_review" href="/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid", section on 'Treatment'</a>.)</p><p>When treating patients with severe, refractory oral MMP, we typically utilize a higher dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> than the dose we use as initial therapy for patients with moderate to severe oral MMP. We prescribe <strong>1 mg/kg per day of prednisone </strong>in addition to one of the following immunosuppressive agents [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azathioprine</strong> (2 to 2.5 mg/kg per day; dose adjustments may be indicated based upon thiopurine methyltransferase [TPMT] activity)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycophenolate</strong><strong> mofetil</strong> (1 to 2.5 g per day)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclophosphamide</strong> (1 to 2 mg/kg per day)</p><p></p><p>We continue treatment with both drugs until disease control is achieved and has remained stable for at least four to six months. We then attempt to taper <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> gradually (eg, over another four to six months) while maintaining the dose of the nonsteroidal immunosuppressant. Once disease control is maintained without prednisone for four to six months, we attempt a slow taper to treatment discontinuation. However, because MMP is a chronic disease, most patients require continuation of some level of therapy. Whenever feasible, we attempt to maintain improvement with local rather than systemic therapy. (See <a class="local">'Mild disease'</a> above.)</p><p>Other regimens may be beneficial. Based upon the findings of a retrospective study of six patients with MMP, combination therapy with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a>, and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil may be another useful treatment regimen for oral MMP [<a href="#rid33">33</a>]. In another retrospective study, 9 of 13 patients given oral <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> without systemic glucocorticoids responded to this treatment [<a href="#rid34">34</a>].</p><p>Potential adverse effects of immunosuppressive therapies include bone marrow suppression and increased risk for infection or malignancy. The adverse effects of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H15289544"><span class="h3">Biologic therapies</span><span class="headingEndMark"> — </span>Intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> may be effective for oral MMP. The high cost of these agents is a potentially limiting factor for their use.</p><p class="headingAnchor" id="H15289551"><span class="h4">Intravenous immune globulin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> (1 to 2 g/kg body weight administered over two to three days every two to six weeks for four to six months) is an often well-tolerated therapy that may be beneficial for patients with severe, refractory MMP, although the response to treatment is variable [<a href="#rid35">35-42</a>]. The use of IVIG for oral MMP is supported by a retrospective study of 20 patients with severe oral MMP in which 12 patients were treated with conventional immunosuppressive therapy and 8 patients, in whom conventional therapy was contraindicated, were treated with IVIG (1 to 2 g/kg per three-day cycle, initially repeated every four weeks). The mean follow-up period was four years. Patients treated with IVIG had better outcomes than those treated with conventional therapy; IVIG-treated patients had significantly shorter durations of treatment, fewer relapses, higher remission rates, fewer adverse effects, and better quality-of-life assessments [<a href="#rid40">40</a>]. The mean time to disease control was six months for patients who received IVIG compared with approximately nine months for patients who received conventional therapy.</p><p><a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> (1 to 2 g/kg per three-day cycle, initially repeated every four weeks) also appeared to be effective in an uncontrolled study of 15 patients with severe MMP involving multiple mucosal surfaces that was poorly responsive to conventional immunosuppressive therapies [<a href="#rid41">41</a>]. All patients responded to therapy and were eventually able to discontinue concurrent systemic treatments. Treatment efficacy was evident within a mean of five months.</p><p>The frequency of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> infusions is slowly tapered once disease control is attained, often by progressively increasing the period between treatments by two weeks and discontinuing treatment after a 16-week, disease-free interval occurs [<a href="#rid40">40,41</a>]. Potentially severe adverse effects of IVIG include anaphylaxis (especially in patients with immunoglobulin A [IgA] deficiency), aseptic meningitis, acute renal failure, hypertension, thrombotic events, and fluid overload. Other adverse effects of IVIG include headache, back pain, chills, fever, flushing, myalgias, hypertension, nausea, vomiting, and phlebitis at the site of infusion. The adverse effects of IVIG are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a>.)</p><p>Achievement of long-term remission in MMP with <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> has been reported. In a retrospective study of six patients with MMP (including ocular involvement) who failed to respond to conventional therapy or who could not tolerate long-term systemic glucocorticoid therapy, all maintained remission of ocular disease for up to nine years [<a href="#rid43">43</a>]. The initial frequency of IVIG cycles was every two to four weeks. Intervals between treatments were gradually lengthened to 16 weeks following achievement of disease control. Systemic glucocorticoids and other immunosuppressive therapies were gradually tapered during IVIG therapy.</p><p class="headingAnchor" id="H15289565"><span class="h4">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a>, a chimeric, murine/human immunoglobulin G1 (IgG1) kappa monoclonal antibody directed against CD20 on pre-B and B lymphocytes, has been used successfully for the treatment of severe MMP [<a href="#rid42">42,44-51</a>]. The drug usually is given in combination with a systemic glucocorticoid, with or without other immunosuppressive agents:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 25 patients with severe, refractory MMP involving the eyes, pharynx, larynx, or esophagus (including five patients classified as having mucous membrane predominant epidermolysis bullosa acquisita), one cycle of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (375 mg/m<sup>2</sup> given weekly for four weeks) was associated with complete responses in 17 patients (68 percent) [<a href="#rid45">45</a>]. All patients were simultaneously treated with <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>, and/or immunosuppressants.</p><p></p><p class="bulletIndent1">The median time to remission after one cycle of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> was 12 weeks, and five additional patients responded completely after a second cycle. Relapses were common after treatment; 10 patients who achieved complete responses after one cycle of rituximab relapsed (mean time to relapse = four months after a complete response). However, seven of eight of the relapsed patients regained complete responses after a second cycle of rituximab. Two patients who were simultaneously treated with conventional immunosuppressants and high-dose systemic glucocorticoids died due to serious infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study including a total of 49 patients with moderate to severe MMP treated with conventional immunosuppressive therapy, 24 patients who had failed therapy with immunosuppressants were concurrently treated with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (four weekly infusions of 375 mg/m<sup>2</sup> or two infusions of 1000 mg given 15 days apart) [<a href="#rid49">49</a>]. Eleven patients received a single course of rituximab, whereas 13 required 2 to 16 additional infusions.</p><p></p><p class="bulletIndent1">All 24 patients treated with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> achieved disease control an average of 10 months after the first dose of rituximab; of the 25 patients treated with conventional therapy alone, 10 achieved disease control an average of 38 months after starting immunosuppressive therapy. Relapse occurred in 10 of the 24 patients treated with rituximab 3 to 19 months after complete response and was controlled with additional rituximab therapy in five patients. Three of the 10 patients who achieved disease control with conventional therapy relapsed after one to three months and required increased immunosuppressive therapy to regain control.</p><p></p><p>Additional data on <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in patients with ocular MMP are reviewed separately. (See  <a class="medical medical_review" href="/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid", section on 'Rituximab'</a>.)</p><p>Adverse effects of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> include dizziness, nausea, itching, fever, chills, sneezing, myalgias, weakness, and/or dyspnea. Severe adverse effects of rituximab include severe infusion reactions, tumor lysis syndrome, acute renal failure, severe mucocutaneous reactions, cardiac arrhythmias, angina, and progressive multifocal leukoencephalopathy. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H864849644"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Examples of additional agents that have been reported to be effective in small numbers of patients include tetracyclines with <a class="drug drug_general" data-topicid="9696" href="/d/drug information/9696.html" rel="external">nicotinamide</a> [<a href="#rid52">52</a>], <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> [<a href="#rid53">53,54</a>], sulfapyridine [<a href="#rid20">20</a>], <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> [<a href="#rid55">55</a>], <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> [<a href="#rid56">56</a>], <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> [<a href="#rid57">57</a>], <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> [<a href="#rid58">58-60</a>], <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid61">61</a>], and <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H86588944"><span class="h2">Adjunctive measures</span><span class="headingEndMark"> — </span>Patients with oral involvement should follow a strict regimen of oral hygiene to avert the accumulation of plaque, the loss of gingiva, and acceleration of tooth decay. This includes brushing of the teeth two to three times each day along with daily flossing and obtaining regular dental cleanings every three to four months. Use of a pediatric toothbrush with soft bristles, toothpaste that lacks sodium lauryl sulfate, and mouthwashes free of alcohol facilitate patient compliance with oral hygiene measures by minimizing pain.</p><p>Topical anesthetics (eg, viscous <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, topical <a class="drug drug_general" data-topicid="9397" href="/d/drug information/9397.html" rel="external">dyclonine</a>) may be used to reduce pain. Patients may apply topical anesthetics before meals, toothbrushing, dental procedures, or other occasions in which pain control is required. The anesthetic should be manually applied directly to painful erosions, rather than used as a mouth rinse. Care should be taken to avoid spread of the anesthetic to pharyngeal, hypopharyngeal, or laryngeal areas to diminish the likelihood of aspiration.</p><p class="headingAnchor" id="H86588898"><span class="h1">EXTRAORAL DISEASE</span><span class="headingEndMark"> — </span>Patients with extraoral mucous membrane pemphigoid (MMP; ocular, nasal, laryngeal, esophageal, or anogenital MMP) are considered to be at high risk for developing serious functional limitations as a consequence of mucosal inflammation and scarring. Thus, the approach to the treatment of patients with these manifestations of MMP differs from the approach to patients with only oral disease. Overall, pharmacologic therapy is more aggressive; systemic agents are often utilized initially regardless of the severity of disease [<a href="#rid1">1</a>]. In addition, early involvement of ophthalmologists, otolaryngologists, and gastroenterologists are indicated for patients with ocular, laryngeal, or esophageal symptoms, respectively. Consultation with an urologist or colorectal surgeon may be useful for patients with anogenital disease.</p><p>Data are limited on the management of patients with nonocular extraoral MMP. In general, the approach to drug therapy of nasal, laryngeal, esophageal, and anogenital MMP mirrors the approach to ocular involvement [<a href="#rid1">1,25</a>]. The treatment of ocular MMP (ocular cicatricial pemphigoid) is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid", section on 'Treatment'</a>.)</p><p>In addition to systemic pharmacologic therapy, other interventions may be useful for managing the extraoral manifestations of MMP:</p><p class="bulletIndent1"><span class="glyph">●</span>Nasal involvement:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Twice-daily irrigation of nasal passages with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or tap water via a bulb syringe, a piston syringe, a neti pot, or a nasal irrigation device helps to gently remove crusts.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Humidified environment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nasal emollients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Topical corticosteroid nasal sprays or drops.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Esophageal involvement:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Soft diet</p><p class="bulletIndent2"><span class="glyph">•</span>Interventions to diminish gastroesophageal reflex and/or gastric acidity</p><p class="bulletIndent2"><span class="glyph">•</span>Esophageal dilation of strictures</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anogenital involvement:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Topical corticosteroids or topical calcineurin inhibitors</p><p class="bulletIndent2"><span class="glyph">•</span>Stool softeners</p><p class="bulletIndent2"><span class="glyph">•</span>Dilation</p><p></p><p>Adjunctive measures for ocular MMP (eg, lubrication, lid hygiene, and management of trichiasis) are reviewed separately. (See  <a class="medical medical_review" href="/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid", section on 'Ocular care'</a>.)</p><p class="headingAnchor" id="H1574319610"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/132083.html" rel="external">"Society guideline links: Mucous membrane pemphigoid"</a>.)</p><p class="headingAnchor" id="H864849990"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease overview</strong> – Mucous membrane pemphigoid (MMP) is a rare, autoimmune blistering and erosive disorder that may affect multiple mucous membranes. The oral cavity is the most common site of involvement  (<a class="graphic graphic_picture graphicRef52208 graphicRef63997 graphicRef73874" href="/d/graphic/52208.html" rel="external">picture 1A-C</a>). (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Clinical features of mucous membrane pemphigoid'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to treatment</strong> – The approach to the treatment of MMP is influenced by the site(s) of mucosal involvement and the severity of disease. Multidisciplinary management is often needed to minimize risk for adverse sequelae of this disease. (See <a class="local">'Approach to treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild disease</strong> – Patients with mild oral MMP (patchy, localized involvement of the oral mucosa) may respond well to local therapy. For patients with mild oral MMP, we suggest a high-potency topical corticosteroid as initial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and intralesional corticosteroid injections are additional options for local therapy. (See <a class="local">'Mild disease'</a> above.)</p><p></p><p class="bulletIndent1">Gingival trays may facilitate treatment of patients with significant gingival involvement by allowing application of topical corticosteroids to lesional sites under occlusion. Patients who have difficulty applying topical corticosteroids directly to affected sites may benefit from treatment with a corticosteroid mouth rinse. (See <a class="local">'Administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate to severe disease or disease resistant to local therapy</strong> – Patients with extensive oral involvement or who fail to improve adequately with local therapy are candidates for systemic treatment. We suggest treating these patients with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We use prednisone more frequently based upon personal experience of better results with this drug. However, the side effect profile of prednisone is a limiting factor for therapy. (See <a class="local">'Moderate to severe disease'</a> above and  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="bulletIndent1">Since long-term treatment with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> therapy is not desired, topical or systemic glucocorticoid-sparing agents (eg, <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil) are used to maintain improvement during and after prednisone tapering. (See <a class="local">'Systemic glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe, refractory disease</strong> – Patients with severe, refractory MMP may benefit from more aggressive therapy. High-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> given in combination with immunosuppressants, intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> are options for therapy. (See <a class="local">'Severe and refractory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extraoral disease</strong> – Pharmacologic therapy for the nonoral forms of MMP is similar to the approach used for ocular MMP (ocular cicatricial pemphigoid). Nonpharmacologic interventions are also useful for the management of these patients. (See <a class="local">'Extraoral disease'</a> above and  <a class="medical medical_review" href="/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid", section on 'Treatment'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370.</a></li><li><a class="nounderline abstract_t">Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000; 43:571.</a></li><li><a class="nounderline abstract_t">Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 2002; 138:380.</a></li><li><a class="nounderline abstract_t">Lazarova Z, Yancey KB. Cicatricial pemphigoid: immunopathogenesis and treatment. Dermatologic Therapy 2002; 15:382.</a></li><li><a class="nounderline abstract_t">Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003; :CD004056.</a></li><li><a class="nounderline abstract_t">Murrell DF, Marinovic B, Caux F, et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol 2015; 72:168.</a></li><li><a class="nounderline abstract_t">Ahmed AR, Hombal SM. Cicatricial pemphigoid. Int J Dermatol 1986; 25:90.</a></li><li><a class="nounderline abstract_t">Lee MS, Wakefield PE, Konzelman JL Jr, James WD. Oral insertable prosthetic device as an aid in treating oral ulcers. Arch Dermatol 1991; 127:479.</a></li><li><a class="nounderline abstract_t">Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla A, et al. Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:688.</a></li><li><a class="nounderline abstract_t">Assmann T, Becker J, Ruzicka T, Megahed M. Topical tacrolimus for oral cicatricial pemphigoid. Clin Exp Dermatol 2004; 29:674.</a></li><li><a class="nounderline abstract_t">Lee HY, Blazek C, Beltraminelli H, Borradori L. Oral mucous membrane pemphigoid: complete response to topical tacrolimus. Acta Derm Venereol 2011; 91:604.</a></li><li><a class="nounderline abstract_t">Suresh L, Martinez Calixto LE, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist 2006; 26:66.</a></li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051760.htm (Accessed on November 01, 2012).</li><li><a class="nounderline abstract_t">Ahmed AR, Kurgis BS, Rogers RS 3rd. Cicatricial pemphigoid. J Am Acad Dermatol 1991; 24:987.</a></li><li><a class="nounderline abstract_t">Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 2009; 10:383.</a></li><li><a class="nounderline abstract_t">Rogers RS 3rd, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982; 6:215.</a></li><li><a class="nounderline abstract_t">Ciarrocca KN, Greenberg MS. A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:159.</a></li><li><a class="nounderline abstract_t">Arash A, Shirin L. The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid. J Oral Pathol Med 2008; 37:341.</a></li><li><a class="nounderline abstract_t">Matthews RW, Pinkney RC, Scully C. The management of intransigent desquamative gingivitis with Dapsone. Ann Dent 1989; 48:41.</a></li><li><a class="nounderline abstract_t">Rogers RS 3rd, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988; 7:201.</a></li><li><a class="nounderline abstract_t">Hegarty AM, Ormond M, Sweeney M, Hodgson T. Dapsone efficacy and adverse events in the management of mucous membrane pemphigoid. Eur J Dermatol 2010; 20:223.</a></li><li><a class="nounderline abstract_t">Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527.</a></li><li><a class="nounderline abstract_t">Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991; 10:185.</a></li><li class="breakAll">Hall RP, Mickle CP. Dapsone. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier Inc, 2007. p.239.</li><li><a class="nounderline abstract_t">Kourosh AS, Yancey KB. Therapeutic approaches to patients with mucous membrane pemphigoid. Dermatol Clin 2011; 29:637.</a></li><li><a class="nounderline abstract_t">Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008; 115:253.</a></li><li><a class="nounderline abstract_t">Megahed M, Schmiedeberg S, Becker J, Ruzicka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 2001; 45:256.</a></li><li><a class="nounderline abstract_t">Lugović L, Buljan M, Situm M, et al. Unrecognized cicatricial pemphigoid with oral manifestations and ocular complications. A case report. Acta Dermatovenerol Croat 2007; 15:236.</a></li><li><a class="nounderline abstract_t">Korman NJ. Update on the use of azathioprine in the management of pemphigus and bullous pemphigoid. Med Surg Dermatol 1996; 3:209.</a></li><li><a class="nounderline abstract_t">Korman NJ. Update on the use of cyclophosphamide in the management of pemphigus, bullous pemphigoid, and cicatricial pemphigoid. Med Surg Dermatol 1998; 5:1.</a></li><li><a class="nounderline abstract_t">Doycheva D, Deuter C, Blumenstock G, et al. Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. Ocul Immunol Inflamm 2011; 19:431.</a></li><li><a class="nounderline abstract_t">Nottage JM, Hammersmith KM, Murchison AP, et al. Treatment of mucous membrane pemphigoid with mycophenolate mofetil. Cornea 2013; 32:810.</a></li><li><a class="nounderline abstract_t">Staines K, Hampton PJ. Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114:e49.</a></li><li><a class="nounderline abstract_t">Munyangango EM, Le Roux-Villet C, Doan S, et al. Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid. Br J Dermatol 2013; 168:381.</a></li><li><a class="nounderline abstract_t">Segura S, Iranzo P, Martínez-de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 2007; 56:960.</a></li><li><a class="nounderline abstract_t">Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999; 106:2136.</a></li><li><a class="nounderline abstract_t">Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003; 139:1051.</a></li><li><a class="nounderline abstract_t">Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004; 111:1380.</a></li><li><a class="nounderline abstract_t">Letko E, Miserocchi E, Daoud YJ, et al. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 2004; 111:303.</a></li><li><a class="nounderline abstract_t">Ahmed AR, Colón JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol 2001; 137:1181.</a></li><li><a class="nounderline abstract_t">Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002; 102:59.</a></li><li><a class="nounderline abstract_t">Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010; 117:861.</a></li><li><a class="nounderline abstract_t">Leuci S, Amato M, Calabria E, et al. Long-Term Follow-Up after Intravenous Immunoglobulin Therapy in Patients with Severe Ocular Mucous Membrane Pemphigoid Unresponsive to Conventional Therapy. J Ophthalmol 2018; 2018:8372146.</a></li><li><a class="nounderline abstract_t">Ross AH, Jaycock P, Cook SD, et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol 2009; 93:421.</a></li><li><a class="nounderline abstract_t">Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 2011; 147:843.</a></li><li><a class="nounderline abstract_t">Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65:552.</a></li><li><a class="nounderline abstract_t">Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol 2013; 68:499.</a></li><li><a class="nounderline abstract_t">Heelan K, Walsh S, Shear NH. Treatment of mucous membrane pemphigoid with rituximab. J Am Acad Dermatol 2013; 69:310.</a></li><li><a class="nounderline abstract_t">Maley A, Warren M, Haberman I, et al. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol 2016; 74:835.</a></li><li><a class="nounderline abstract_t">Lamberts A, Euverman HI, Terra JB, et al. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. Front Immunol 2018; 9:248.</a></li><li><a class="nounderline abstract_t">Haefliger S, Horn MP, Suter VG, et al. Rituximab for the Treatment of Isolated Refractory Desquamative Gingivitis Due to Mucous Membrane Pemphigoid. JAMA Dermatol 2016; 152:1396.</a></li><li><a class="nounderline abstract_t">Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol 1998; 23:254.</a></li><li><a class="nounderline abstract_t">Carrozzo M, Arduino P, Bertolusso G, et al. Systemic minocycline as a therapeutic option in predominantly oral mucous membrane pemphigoid: a cautionary report. Int J Oral Maxillofac Surg 2009; 38:1071.</a></li><li><a class="nounderline abstract_t">Carrozzo M, Arduino PG, Baldovino S, et al. Minocycline in combination with mycophenolate mofetil in oral mucous membrane pemphigoid. Eur J Dermatol 2008; 18:198.</a></li><li><a class="nounderline abstract_t">Duong DJ, Moxley RT 3rd, Kellman RM, et al. Thalidomide therapy for cicatricial pemphigoid. J Am Acad Dermatol 2002; 47:S193.</a></li><li><a class="nounderline abstract_t">Saeed L, Schmidt TH, Gensler LS, et al. Successful treatment of mucous membrane pemphigoid with bortezomib. JAAD Case Rep 2018; 4:81.</a></li><li><a class="nounderline abstract_t">Sarny S, Hucke M, El-Shabrawi Y. Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib. JAMA Ophthalmol 2018; 136:1420.</a></li><li><a class="nounderline abstract_t">Prey S, Robert PY, Drouet M, et al. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept. Acta Derm Venereol 2007; 87:74.</a></li><li><a class="nounderline abstract_t">John H, Whallett A, Quinlan M. Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha. Eye (Lond) 2007; 21:1434.</a></li><li><a class="nounderline abstract_t">Kennedy JS, Devillez RL, Henning JS. Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept. J Drugs Dermatol 2010; 9:68.</a></li><li><a class="nounderline abstract_t">Heffernan MP, Bentley DD. Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol 2006; 142:1268.</a></li><li><a class="nounderline abstract_t">James H, Paley GL, Brasington R, et al. Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep 2021; 22:101104.</a></li></ol></div><div id="topicVersionRevision">Topic 83575 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11902988" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11004612" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11902989" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cicatricial pemphigoid: immunopathogenesis and treatment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12535507" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25443626" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3516897" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2006873" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Oral insertable prosthetic device as an aid in treating oral ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12789149" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15550151" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Topical tacrolimus for oral cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21597668" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral mucous membrane pemphigoid: complete response to topical tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16681241" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Successful treatment of mucous membrane pemphigoid with tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16681241" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Successful treatment of mucous membrane pemphigoid with tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1869688" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19824739" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7037880" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468458" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A retrospective study of the management of oral mucous membrane pemphigoid with dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18331284" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2675748" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The management of intransigent desquamative gingivitis with Dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3153445" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dapsone therapy of cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20123643" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Dapsone efficacy and adverse events in the management of mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3296406" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2055022" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Systemic chemotherapy for ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2055022" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Systemic chemotherapy for ocular cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21925010" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Therapeutic approaches to patients with mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17655931" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11464188" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18093453" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Unrecognized cicatricial pemphigoid with oral manifestations and ocular complications. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Update on the use of azathioprine in the management of pemphigus and bullous pemphigoid</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Update on the use of cyclophosphamide in the management of pemphigus, bullous pemphigoid, and cicatricial pemphigoid</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22106912" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23132447" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of mucous membrane pemphigoid with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22727107" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22963186" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17368865" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571350" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925395" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15234140" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15183151" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559214" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781068" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20045562" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30327726" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Long-Term Follow-Up after Intravenous Immunoglobulin Therapy in Patients with Severe Ocular Mucous Membrane Pemphigoid Unresponsive to Conventional Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321473" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422323" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rituximab for patients with refractory mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21641080" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23200198" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23866864" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of mucous membrane pemphigoid with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26936298" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29520266" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27732708" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Rituximab for the Treatment of Isolated Refractory Desquamative Gingivitis Due to Mucous Membrane Pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233619" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628373" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Systemic minocycline as a therapeutic option in predominantly oral mucous membrane pemphigoid: a cautionary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18424391" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Minocycline in combination with mycophenolate mofetil in oral mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12140460" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Thalidomide therapy for cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29387757" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Successful treatment of mucous membrane pemphigoid with bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30242383" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17225020" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17693996" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20120429" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043180" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Successful treatment of mucous membrane pemphigoid with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34007952" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Tofacitinib for refractory ocular mucous membrane pemphigoid.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
